Skip to main content

Toxicity, health-related quality of life and sexuality after molecular profile-based adjuvant treatment in high-intermediate risk endometrial cancer, PORTEC-4a

In brief

Profile-guided treatment reduced mild side effects without worsening quality of life

Among 564 patients with early-stage, high-intermediate-risk endometrial cancer, profile-guided treatment led to fewer grade 1-2 side effects at treatment completion than standard vaginal brachytherapy: 28% versus 45%. Severe side effects were similar and rare, and quality of life stayed near age-matched norms; sexual activity was lower, often for reasons unrelated to the cancer.

Journal
British journal of cancer (Q1)
Published
11 November 2026
Study design
Randomized controlled trial
Evidence level
Level 5, Expert Opinion (CEBM 5)
Authors
Anne Sophie V M Van den Heerik, Cathalijne C B Post, Marie A D Haverkort, Nienke Kuijsters, Stefan Kommoss, Friederike L A Koppe, et al.
PMID
43015360
DOI
10.1038/s41416-026-03642-4

Why clinicians should know about it

  • Picked for Radiation Oncology (paper of the day, 16 November 2026): Randomized adjuvant strategy; radiotherapy de-escalation and toxicity

Abstract

BACKGROUND: PORTEC-4a was the first to incorporate molecular-integrated profile-guided adjuvant treatment in early-stage high-intermediate-risk endometrial cancer (EC), demonstrating non-inferiority. Here, adverse events (AE), health-related quality of life (HRQoL) and sexual health are reported. METHODS: 564 patients were randomised to molecular-based adjuvant treatment (n = 367) or standard vaginal brachytherapy (VBT, n = 197). In the molecular-profile arm, patients underwent observation, VBT or pelvic radiotherapy according to molecular-integrated profile. HRQoL and sexual functioning were assessed with EORTC QLQ-C30 and EN24 modules and compared with age-matched normative data. RESULTS: Median follow-up was 58.1 months; 523 (92.7%) patients were evaluable. Grade 1-2 AEs were less frequent in the molecular-profile arm at treatment completion compared with the standard arm (28.3% vs. 45.2%, p < 0.01), without differences in grade 3-4 AEs (p = 0.46). Throughout follow-up, treatment-related grade 3-4 AEs were rare (1% vs. 2%). HRQoL remained comparable to normative data over time. Sexual interest/activity was similar between arms, but lower than normative values. 75.5% of patients reported ≥1 reason for sexual inactivity; disease-related sexual inactivity decreased from 24.2% to 9.2% at 3 years. CONCLUSION: Molecular-guided adjuvant treatment for patients with high-intermediate riskEC is associated with low toxicity, preserved HRQoL and slightly reduced sexual activity due to personal factors (no partner, sex not important in their relationship or partner-related medical issues) rather than their own illness.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.